=> d l9
L9 HAS NO ANSWERS
L9 STR



VPA 7-3/4/5 U
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 3 8
NUMBER OF NODES IS 16

STEREO ATTRIBUTES: NONE

=> s l9 ful
FULL SEARCH INITIATED 18:16:41 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 554156 TO ITERATE

100.0% PROCESSED 554156 ITERATIONS 108 ANSWERS
SEARCH TIME: 00.00.03

L11 108 SEA SSS FUL L9

L15 ANSWER 1 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2007:401906 CAPLUS
DN 147:30994
TI Ring-chain tautomerism of simplified analogues of isoniazid-NAD(P) adducts: an experimental and theoretical study
AU Delaine, Tamara; Bernardes-Genisson, Vania; Stigliani, Jean-Luc; Gornitzka, Heinz; Meunier, Bernard; Bernadou, Jean
CS Laboratoire de Chimie de Coordination du CNRS, Toulouse, 31077, Fr.
SO European Journal of Organic Chemistry (2007), (10), 1624-1630
CODEN: EJOCFK; ISSN: 1434-193X
PB Wiley-VCH Verlag GmbH & Co. KGaA
DT Journal
LA English
OS CASREACT 147:30994
GI



AB Simplified analogs of oxidized and reduced isoniazid-NAD(P) adducts were prepared to study their behavior with regard to ring-chain tautomeric isomerism in solution In DMSO the oxidized analogs, pyridinium salts I (R = Ph, 3-chloro-4-pyridyl), and the corresponding 1,2-dihydropyridines II were found to exist exclusively in the ring (cyclic hemiamidal) form shown. In contrast, the 1,4-dihydropyridine analogs III were present in the ring (shown) and/or chain forms depending on the nature of the aromatic substituent. Thus, the 1,4-dihydropyridines III (R = Ph, 3-chloro-4-pyridyl) are, in solution, preferentially in the keto-amide chain form, whereas III (R = 4-pyridyl), which is the closest model of the isoniazid-NAD(P) adduct, exists as ring (major) and chain (minor) tautomers in equilibrium The ratio of the tautomeric forms involved in the equilibrium of this system is also influenced by the polarity of the solvent with a shift towards the ring tautomer when the polarity of the solvent is increased. Complementary computational studies were performed by using quantum chemical calcns. (B3LYP/6-31G**) and frontier MO anal., which allowed the key structural factors involved in the ring-chain tautomerism equilibrium to be discussed.
IT 926292-31-1 938449-43-5 938449-46-8
RL: PRP (Properties)
(exptl. and theor. study of ring-chain tautomerism of 4-aroyldihydropyridine-3-carboxamides as simplified analogs of isoniazid-NAD(P) adducts)
RN 926292-31-1 CAPLUS
CN 1(4H)-Pyridineacetic acid, 3-(aminocarbonyl)-4-(4-pyridinylcarbonyl)-, ethyl ester (CA INDEX NAME)



RN 938449-43-5 CAPLUS
CN 3-Pyridinecarboxamide, 4-[(3-chloro-4-pyridinyl)carbonyl]-1,4-dihydro-1-methyl- (CA INDEX NAME)



RN 938449-46-8 CAPLUS
CN 3-Pyridinecarboxamide, 1,4-dihydro-1-methyl-4-(4-pyridinylcarbonyl)- (CA INDEX NAME)



IT 938449-34-4P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(exptl. and theor. study of ring-chain tautomerism of 4-aroyldihydropyridine-3-carboxamides as simplified analogs of isoniazid-NAD(P) adducts)
RN 938449-34-4 CAPLUS
CN 1(4H)-Pyridineacetic acid, 3-(aminocarbonyl)-4-[(3-chloro-4-pyridinyl)carbonyl]-, ethyl ester (CA INDEX NAME)



RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:991014 CAPLUS
DN 145:145570
TI A novel method for the synthesis of carbon-14-labeled N-[3-(1-methyl-4-piperidinyl)-1H-pyrrolo[3,2-b]pyridin-5-yl]propanamide and its use in quantitative whole-body autoradiography studies
AU Wheeler, William J.; Chay, Sylvia H.; Herman, Jennifer L.; O'Bannon, Douglas D.
CS Lilly Research Laboratories, A Division of Eli Lilly and Company, Indianapolis, IN, 46285, USA
SO Journal of Labelled Compounds & Radiopharmaceuticals (2005), 48(9), 669-681
CODEN: JLCRD4; ISSN: 0362-4803
PB John Wiley & Sons Ltd.
DT Journal
LA English
OS CASREACT 145:145570
GI



I

AB Sumitriptan, a non-selective 5-HT1B/1D agonist is an effective therapeutic agent for the acute treatment of migraine, but it is contraindicated for use in patients with known heart disease. The first Selective Serotonin One F Receptor Agonist (SSOFRA), 5-(4'-fluorobenzamido)-3-(N-methyl-piperidin-4-yl)-1H-indole was demonstrated to be clin. useful in the treatment of migraine. Although it exhibited high affinity for the 5-HT1F receptor as well as high selectivity for the 5-HT1F receptor relative to 5-HT1B and 5-HT1D receptors, it demonstrated appreciable affinity for the 5-HT1A receptor. Subsequently, a program was launched to discover SSOFRA's with improved selectivity over other 5-HT1 receptor subtypes. As a result of these efforts, N-[3-(1-methyl-4-piperidinyl)-1H-pyrrolo[3,2-b]pyridin-5-yl]propanamide (I) was found to possess greater than 100-fold selectivity over 5-HT1A, 5-HT1B and 5-HT1D receptors. Pursuant to a potential clin. investigation of I, its carbon-14-labeled isotopomer has been prepared by a circuitous route from unlabeled I and used in quant. whole-body autoradiog. studies in rats. The results of these efforts are reported herein.

IT 899827-19-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and pharmacokinetics of C14-labeled propanoylamino(methylpiperidinyl)pyrrolopyridine succinate via oxidative cleavage of acetylamino(methylpiperidinyl)indole followed by cyclization reduction, and addition of succinic acid)

RN 899827-19-1 CAPLUS
CN Propanamide, N-[5-(formylamino)-6-[(1-methyl-4-piperidinyl)carbonyl]-2-pyridinyl]- (CA INDEX NAME)



RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

AN 2005:991014 CAPLUS
DN 145:145570
TI A novel method for the synthesis of carbon-14-labeled N-[3-(1-methyl-4-piperidinyl)-1H-pyrrolo[3,2-b]pyridin-5-yl]propanamide and its use in quantitative whole-body autoradiography studies
AU Wheeler, William J.; Chay, Sylvia H.; Herman, Jennifer L.; O'Bannon, Douglas D.
CS Lilly Research Laboratories, A Division of Eli Lilly and Company, Indianapolis, IN, 46285, USA
SO Journal of Labelled Compounds & Radiopharmaceuticals (2005), 48(9), 669-681
CODEN: JLCRD4; ISSN: 0362-4803
PB John Wiley & Sons Ltd.
DT Journal
LA English
OS CASREACT 145:145570
GI



I

AB Sumitriptan, a non-selective 5-HT1B/1D agonist is an effective therapeutic agent for the acute treatment of migraine, but it is contraindicated for use in patients with known heart disease. The first Selective Serotonin One F Receptor Agonist (SSOFRA), 5-(4'-fluorobenzamido)-3-(N-methyl-piperidin-4-yl)-1H-indole was demonstrated to be clin. useful in the treatment of migraine. Although it exhibited high affinity for the 5-HT1F receptor as well as high selectivity for the 5-HT1F receptor relative to 5-HT1B and 5-HT1D receptors, it demonstrated appreciable affinity for the 5-HT1A receptor. Subsequently, a program was launched to discover SSOFRA's with improved selectivity over other 5-HT1 receptor subtypes. As a result of these efforts, N-[3-(1-methyl-4-piperidinyl)-1H-pyrrolo[3,2-b]pyridin-5-yl]propanamide (I) was found to possess greater than 100-fold selectivity over 5-HT1A, 5-HT1B and 5-HT1D receptors. Pursuant to a potential clin. investigation of I, its carbon-14-labeled isotopomer has been prepared by a circuitous route from unlabeled I and used in quant. whole-body autoradiog. studies in rats. The results of these efforts are reported herein.

IT 899827-19-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and pharmacokinetics of C14-labeled propanoylamino(methylpiperidinyl)pyrrolopyridine succinate via oxidative cleavage of acetylamino(methylpiperidinyl)indole followed by cyclization reduction, and addition of succinic acid)

RN 899827-19-1 CAPLUS
CN Propanamide, N-[5-(formylamino)-6-[(1-methyl-4-piperidinyl)carbonyl]-2-pyridinyl]- (CA INDEX NAME)



RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

AN 2007:401906 CAPLUS
DN 147:30994
TI Ring-chain tautomerism of simplified analogues of isoniazid-NAD(P) adducts: an experimental and theoretical study
AU Delaine, Tamara; Bernardes-Genisson, Vania; Stigliani, Jean-Luc; Gornitzka, Heinz; Meunier, Bernard; Bernadou, Jean
CS Laboratoire de Chimie de Coordination du CNRS, Toulouse, 31077, Fr.
SO European Journal of Organic Chemistry (2007), (10), 1624-1630
CODEN: EJOCFK; ISSN: 1434-193X
PB Wiley-VCH Verlag GmbH & Co. KGaA
DT Journal
LA English
OS CASREACT 147:30994
GI



AB Simplified analogs of oxidized and reduced isoniazid-NAD(P) adducts were prepared to study their behavior with regard to ring-chain tautomeric isomerism in solution In DMSO the oxidized analogs, pyridinium salts I (R = Ph, 3-chloro-4-pyridyl), and the corresponding 1,2-dihydropyridines II were found to exist exclusively in the ring (cyclic hemiamidal) form shown. In contrast, the 1,4-dihydropyridine analogs III were present in the ring (shown) and/or chain forms depending on the nature of the aromatic substituent. Thus, the 1,4-dihydropyridines III (R = Ph, 3-chloro-4-pyridyl) are, in solution, preferentially in the keto-amide chain form, whereas III (R = 4-pyridyl), which is the closest model of the isoniazid-NAD(P) adduct, exists as ring (major) and chain (minor) tautomers in equilibrium The ratio of the tautomeric forms involved in the equilibrium of this system is also influenced by the polarity of the solvent with a shift towards the ring tautomer when the polarity of the solvent is increased. Complementary computational studies were performed by using quantum chemical calcns. (B3LYP/6-31G**) and frontier MO anal., which allowed the key structural factors involved in the ring-chain tautomerism equilibrium to be discussed.
IT 926292-31-1 938449-43-5 938449-46-8
RL: PRP (Properties)
(exptl. and theor. study of ring-chain tautomerism of 4-aroyldihydropyridine-3-carboxamides as simplified analogs of isoniazid-NAD(P) adducts)
RN 926292-31-1 CAPLUS
CN 1(4H)-Pyridineacetic acid, 3-(aminocarbonyl)-4-(4-pyridinylcarbonyl)-, ethyl ester (CA INDEX NAME)



RN 938449-43-5 CAPLUS
CN 3-Pyridinecarboxamide, 4-[(3-chloro-4-pyridinyl)carbonyl]-1,4-dihydro-1-methyl- (CA INDEX NAME)



RN 938449-46-8 CAPLUS
CN 3-Pyridinecarboxamide, 1,4-dihydro-1-methyl-4-(4-pyridinylcarbonyl)- (CA INDEX NAME)



IT 938449-34-4P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(exptl. and theor. study of ring-chain tautomerism of 4-aroyldihydropyridine-3-carboxamides as simplified analogs of isoniazid-NAD(P) adducts)
RN 938449-34-4 CAPLUS
CN 1(4H)-Pyridineacetic acid, 3-(aminocarbonyl)-4-[(3-chloro-4-pyridinyl)carbonyl]-, ethyl ester (CA INDEX NAME)



RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> d l1
L1 HAS NO ANSWERS
L1                STR
```




```
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC   9   3
NUMBER OF NODES IS  14

STEREO ATTRIBUTES: NONE


=> s l1 ful
FULL SEARCH INITIATED 17:57:43 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     8817 TO ITERATE

100.0% PROCESSED     8817 ITERATIONS                                 106 ANSWERS
SEARCH TIME: 00.00.01

L3           106 SEA SSS FUL L1
```




```
ENTER (DIS), GRA, NOD, BON OR ?:end
L4   STRUCTURE CREATED

=> search l4
ENTER TYPE OF SEARCH (SSS), CSS, FAMILY, OR EXACT:sss
ENTER SCOPE OF SEARCH (SAMPLE), FULL, RANGE, OR SUBSET:subset
ENTER SUBSET L# OR (END):l3
ENTER SUBSET SEARCH SCOPE - SAMPLE, FULL, RANGE, OR (END):ful
FULL SUBSET SEARCH INITIATED 17:58:35 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED -      106 TO ITERATE

100.0% PROCESSED      106 ITERATIONS                              15 ANSWERS
SEARCH TIME: 00.00.01

L5            15 SEA SUB=L3 SSS FUL L4
```

```
=> s l5
L6            3 L5

=> d bib abs hitstr 1-3

L6   ANSWER 1 OF 3  CAPLUS  COPYRIGHT 2007 ACS on STN
AN   2004:927173  CAPLUS
DN   141:395422
TI   Preparation of N-[(piperidinyloxy)phenyl]-, N-[(piperidinyloxy)pyridinyl]-
     , N-[(piperidinylsulfanyl)phenyl]-, and N-[(piperidinylsulfanyl)pyridinyl]
     amides as 5-HT1F agonists for treatment of migraine
IN   Blanco-Pillado, Maria-Jesus; Benesh, Dana Rae; Filla, Sandra Ann; Hudziak,
     Kevin John; Mathes, Brian Michael; Kohlman, Daniel Timothy; Ying,
     Bai-Ping; Zhang, Deyi; Xu, Yao-Chang
PA   Eli Lilly and Company, USA
SO   PCT Int. Appl., 186 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.           KIND   DATE        APPLICATION NO.          DATE
     ---------------      ----   --------    --------------------     --------
PI   WO 2004094380         A1    20041104    WO 2004-US9283           20040414
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
             ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
             SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
             TD, TG
     AU 2004232799         A1    20041104    AU 2004-232799           20040414
     CA 2518839            A1    20041104    CA 2004-2518839          20040414
     EP 1626958            A1    20060222    EP 2004-759769           20040414
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
     BR 2004009211         A     20060328    BR 2004-9211             20040414
     CN 1777584            A     20060524    CN 2004-80010411         20040414
     JP 2006523692         T     20061019    JP 2006-509337           20040414
     IN 2005KN01825        A     20070720    IN 2005-KN1825           20050913
     US 2006211734         A1    20060921    US 2005-552131           20051011
     MX 2005PA11223        A     20060126    MX 2005-PA11223          20051018
PRAI US 2003-464396P       P     20030418
     WO 2004-US9283        A     20040414
OS   MARPAT 141:395422
GI
```



I



II

AB Title compds. I [wherein Q = O, S; X = CR4c, N; R1 = (un)substituted alkyl, cycloalkyl(alkyl), Ph, heterocyclyl; R2 = H, (fluoro)alkyl, cycloalkylalkyl, (un)substituted pyrazolyl(alkyl); R3 = H, alkyl; R4a, R4b, R4c = independently H, halo, (fluoro)alkyl; R5, R6 = independently H, (fluoro)alkyl; with the proviso that R6 = alkyl only when R5 ≠ H; and pharmaceutically acceptable acid addition salts thereof] were prepared by standard and solid phase combinatorial methods as 5-HT1F agonists. For example, amidation of [3-[(1-methylpiperidin-4-yl)oxy]phenyl]amine (preparation given) with benzoyl chloride afforded II (91%). In a radioligand binding assay using Ltk cells transfected with the human 5-HT1F receptor sequence, exemplified invention compds. exhibited high affinity for the receptor with Ki values of ≤ 150 nM. Thus, I and their pharmaceutical compns. are useful for activating 5-HT1F receptors, inhibiting neuronal protein extravasation, and treating or preventing migraine in mammals, especially humans (no data).

IT 790671-89-5P 790671-90-8P 790671-91-9P
790671-92-0P 790671-93-1P 790671-94-2P
790671-95-3P 790671-96-4P 790671-97-5P
790671-98-6P 790671-99-7P
RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
(5-HT1F agonist; preparation of piperidinyl-substituted amides as 5-HT1F agonists for treatment of migraine)

RN 790671-89-5 CAPLUS

CN Benzamide, 2,4-difluoro-N-[6-[(1-methyl-4-piperidinyl)thio]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 790671-90-8 CAPLUS
CN Benzamide, 2-chloro-N-[6-[(1-methyl-4-piperidinyl)thio]-2-pyridinyl]-
(9CI) (CA INDEX NAME)



RN 790671-91-9 CAPLUS
CN Cyclopentanecarboxamide, N-[6-[(1-methyl-4-piperidinyl)thio]-2-pyridinyl]-
(9CI) (CA INDEX NAME)



RN 790671-92-0 CAPLUS
CN Cyclohexanecarboxamide, N-[6-[(1-methyl-4-piperidinyl)thio]-2-pyridinyl]-
(9CI) (CA INDEX NAME)



RN 790671-93-1 CAPLUS

CN Benzamide, 2-bromo-N-[6-[(1-methyl-4-piperidinyl)thio]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 790671-94-2 CAPLUS
CN 2-Thiophenecarboxamide, 3-chloro-N-[6-[(1-methyl-4-piperidinyl)thio]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 790671-95-3 CAPLUS
CN Cyclobutanecarboxamide, N-[6-[(1-methyl-4-piperidinyl)thio]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 790671-96-4 CAPLUS

CN Benzamide, 3,4-difluoro-N-[6-[(1-methyl-4-piperidinyl)thio]-2-pyridinyl]-
(9CI) (CA INDEX NAME)



RN 790671-97-5 CAPLUS
CN Benzamide, 2,3,4-trifluoro-N-[6-[(1-methyl-4-piperidinyl)thio]-2-
pyridinyl]- (9CI) (CA INDEX NAME)



RN 790671-98-6 CAPLUS
CN Benzamide, 2,4-dichloro-N-[6-[(1-methyl-4-piperidinyl)thio]-2-pyridinyl]-
(9CI) (CA INDEX NAME)



RN 790671-99-7 CAPLUS
CN Benzamide, 4-fluoro-N-[6-[(1-methyl-4-piperidinyl)thio]-2-pyridinyl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2001:505359 CAPLUS
DN 135:107343
TI Preparation of 1-arylalkylpiperidines and piperazines as 5-HT2A antagonists
IN Ackermann, Karl-August; Boettcher, Henning; Pruecher, Helmut; Van Amsterdam, Christoph; Seyfried, Christoph; Greiner, Hartmut; Bartoszyk, Gerd; Harting, Juergen
PA Merck Patent G.m.b.H., Germany
SO Ger. Offen., 10 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 10000739	A1	20010712	DE 2000-10000739	20000111
	CA 2396007	A1	20010719	CA 2001-2396007	20010105
	WO 2001051469	A1	20010719	WO 2001-EP80	20010105
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	BR 2001007578	A	20021001	BR 2001-7578	20010105
	EP 1246803	A1	20021009	EP 2001-905650	20010105
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	HU 200300052	A2	20030528	HU 2003-52	20010105
	JP 2004500373	T	20040108	JP 2001-551851	20010105
	NO 2002003293	A	20020708	NO 2002-3293	20020708
	MX 2002PA06809	A	20021023	MX 2002-PA6809	20020710
	IN 2002KN01015	A	20050311	IN 2002-KN1015	20020807
	ZA 2002006361	A	20031110	ZA 2002-6361	20020808
	US 2003130287	A1	20030710	US 2002-169399	20021105
PRAI	DE 2000-10000739	A	20000111		

WO 2001-EP80 W 20010105
OS MARPAT 135:107343
GI



I

AB Title compds. [I; R1, R2 = (substituted) phenylalkyl, naphthylalkyl, heterocyclylalkyl; X = CH, N; Y = SO2 if X = N; Y = S, SO, SO2 if B = CH] and salts thereof were prepared as 5-HT2A antagonists (no data). Thus, 1-[2-(4-fluorophenyl)ethyl]piperazine (preparation given) and 8-chlorosulfonylquinoline in CH2Cl2 were stirred with 4-DMAP for 24 h at room temperature to give 4-(8-quinolinesulfonyl)-1-[2-(4-fluorophenyl)ethyl]piperazine.

IT 349664-40-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylalkylpiperidines and piperazines as 5-HT2A antagonists)

RN 349664-40-0 CAPLUS
CN Pyridine, 2-[[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]thio]-6-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L6 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1985:615189 CAPLUS
DN 103:215189
TI Pyridine-2-ethers, especially pyridine-2-thioethers with a nitrogen-containing cycloaliphatic ring
IN Scheffler, Gerhard; Engel, Juergen; Jakovlev, Vladimir; Nickel, Bernd; Thiemer, Klaus
PA Degussa A.-G., Fed. Rep. Ger.
SO Eur. Pat. Appl., 73 pp.
CODEN: EPXXDW
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 149088	A1	19850724	EP 1984-114607	19841201
	EP 149088	B1	19890118		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	ZA 8408275	A	19850828	ZA 1984-8275	19841023
	IL 73608	A	19871231	IL 1984-73608	19841123
	DE 3443968	A1	19851031	DE 1984-3443968	19841201
	AT 40131	T	19890215	AT 1984-114607	19841201
	US 4643995	A	19870217	US 1984-682773	19841217

	DK 8406133	A	19850629	DK 1984-6133	19841220
	AU 8436996	A	19850704	AU 1984-36996	19841220
	AU 566560	B2	19871022		
	GB 2152048	A	19850731	GB 1984-32162	19841220
	GB 2152048	B	19871111		
	SU 1417796	A3	19880815	SU 1984-3826165	19841221
	JP 60169476	A	19850902	JP 1984-272172	19841225
	FI 8405126	A	19850629	FI 1984-5126	19841227
	FI 84062	B	19910628		
	FI 84062	C	19911010		
	NO 8405250	A	19850701	NO 1984-5250	19841227
	NO 164237	B	19900605		
	NO 164237	C	19900912		
	DD 231354	A5	19851224	DD 1984-271863	19841227
	ES 539076	A1	19860516	ES 1984-539076	19841227
	HU 36115	A2	19850828	HU 1984-4869	19841228
	HU 194209	B	19880128		
	CN 85101353	A	19861015	CN 1985-101353	19850401
PRAI	DE 1983-3347276	A	19831228		
	EP 1984-114607	A	19841201		

OS CASREACT 103:215189; MARPAT 103:215189

GI



I



II

AB The title compds. [I; R, R1 = H, alkoxy, phenylalkyl, CF3, OH, cyano, NO2, halo, PhO, CO2H, alkoxycarbonyl, amino, carbamoyl; R2 = quinuclidinyl, tropanyl, Q; R3 = (un)substituted alkyl; Z = O, S, SO, SO2; Z1 = alkylene, bond; n = 0-3; m = 1-6] were prepared Thus, 2,6-dichloropyridine in Me2SO was added dropwise to 1-methyl-4-piperidinethiol in Me2SO containing NaH and the mixture refluxed 3-6 h to give II.HCl. I are effective analgesics with an ED50 of 2.8 mg/kg orally in mice.

IT 99201-63-5P 99201-79-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as analgesic)

RN 99201-63-5 CAPLUS

CN Pyridine, 2-methoxy-6-[(1-methyl-4-piperidinyl)thio]- (9CI) (CA INDEX NAME)



RN 99201-79-3 CAPLUS

CN Pyridine, 2-methoxy-6-[(1-methyl-4-piperidinyl)thio]-, monohydrochloride

(9CI) (CA INDEX NAME)



● HCl